http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015534638-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4406 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate | 2013-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2015534638-A |
| titleOfInvention | Resistant biomarkers for HDAC inhibitors |
| abstract | Provided herein is a method for identifying a cancer patient at risk of resistance to HDAC inhibitor therapy, obtaining a tumor sample from the cancer patient; and testis-specific in the sample Detecting the presence of Y-code-like protein 5 (TSPYL5) expression; quantifying the level of TSPYL5 expression in the sample (here, a high level of TSPYL5 expression compared to the expression criteria defined by TSPYL5) Correlating with resistance to HDAC inhibitor therapy); applying this correlation to identify cancer patients at risk of resistance to HDAC inhibitor therapy. Also provided is a method of identifying a cancer patient with a high likelihood of a positive clinical response to HDAC inhibitor therapy, obtaining a tumor sample from said cancer patient; testis-specific in said sample Detecting the presence of Y-code-like protein 5 (TSPYL5) expression; quantifying the level of TSPYL5 expression in the sample (here, a low level of TSPYL5 expression compared to the expression criteria defined by TSPYL5) Identifying the cancer patient with a high likelihood of a positive clinical response to the HDAC inhibitor therapy). Related methods and compositions are also provided. [Selection] Figure 3 |
| priorityDate | 2012-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 219.